IMWG consensus on risk stratification in multiple myeloma, Leukemia, vol.28, issue.2, pp.269-277, 2013. ,
Genomics of Multiple Myeloma, Journal of Clinical Oncology, vol.35, issue.9, pp.963-967, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01813387
Risk-Based Therapeutic Strategies, The Cancer Journal, vol.25, issue.1, pp.54-58, 2019. ,
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, Journal of Clinical Oncology, vol.33, issue.26, pp.2863-2869, 2015. ,
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, New England Journal of Medicine, vol.373, issue.7, pp.621-631, 2015. ,
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-3495, 2007. ,
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma, Blood, vol.133, issue.11, pp.1217-1221, 2019. ,
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy, Blood, vol.92, issue.3, pp.802-809, 1998. ,
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma, Cells, vol.9, issue.2, p.287, 2020. ,
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis, Leukemia, vol.33, issue.1, pp.159-170, 2018. ,
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, vol.117, issue.18, pp.4691-4695, 2011. ,
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, issue.11, pp.1973-1976, 2010. ,
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma, Haematologica, vol.102, issue.9, pp.e364-e367, 2017. ,